General Dynamics Corporation (GD) Stock Price Today
Aura AI Summary
Key Stats
- $92.28BMarket Cap
- 1,256,447Volume
- IndustrialsSector
- $395.9752W High
- $312.5352W Low
- 87 DaysTypical Hold Time
- $96.92BEnterprise Value
- 1.86%Div Yield
- 0% Sell | 100% BuyTrading Activity
Track General Dynamics Corporation (GD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, General Dynamics Corporation has traded between a low of $312.53 and a high of $395.97, highlighting its annual price range. Buy and sell General Dynamics Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Most Recent News
Home Depot and Lowe's see declining sales amid high mortgage rates and weak housing market.
Home Depot and Lowe's reported declines in comparable transactions in Q3 2026 due to a sluggish housing market and rising mortgage rates now above 7%. This has led to fewer home sales and softer demand for home improvement projects, as consumers dela...

Tesla's Cybercab launch signals robotaxi growth in 2027, urging caution on a SpaceX merger before success.
Tesla has started selling Cybercabs, priced at $29,990 with a $299 monthly subscription, but their current use is limited to specific areas and lacks manual controls. This launch is mainly promotional, highlighting Tesla's focus on becoming a transpo...

FDA approval for Grail's Galleri cancer test expected in early 2027, key for insurer coverage and pricing.
Grail expects FDA approval for its multi-cancer early detection test, Galleri, in Q1 2027, which could lead to Medicare and commercial insurer coverage. Despite a failed primary endpoint in a large NHS trial, Galleri showed promising results for 12 d...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.